Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
Genetic study results show that long-term kidney transplant rejection risk may be increased if the organ donor has a variant form of the multidrug resistance 1 gene.
A new study at the University of Cincinnati seeks to end the questions over generic-vs.-brand for a common immunosuppressive drug for transplant patients, tacrolimus.
Research shows that even partially matched bone marrow transplants are able to eliminate sickle cell disease in some patients with sickle cell anemia.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.
Sirolimus, whether given at the time of liver transplantation or after, is associated with poorer outcomes in patients with hepatitis C virus infection compared with those who do not take the immunosuppressant, shows a US study.
Switching from calcineurin inhibitors to a sirolimus-containing immunosuppression regimen may help reduce the incidence of secondary skin cancer after kidney transplantation, suggests research published in TheNew England Journal of Medicine.
Kidney transplant patients vaccinated against Streptococcus pneumoniae appear to be protected against pneumococcal infection for at least 15 months, research shows.
An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman School of Medicine at the University of Pennsylvania that will be published today in the New England Journal of Medicine.
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.
Veloxis Pharmaceuticals A/S today announced that enrolment has been completed in its pivotal LCP-Tacro Phase III study in de novo kidney transplant patients. The LCP-Tacro 3002 study is designed to demonstrate non-inferiority versus the gold standard therapy Prograf and has randomized over 540 patients at approximately 90 clinical sites around the world.
A new study shows that kids with juvenile idiopathic arthritis develop cancer four times more often than children without the disease, but the treatments they receive - including biologic treatments like Enbrel - may not explain their increased risk. If confirmed, researchers say the findings should ease fears that biologic treatments known as TNF inhibitors cause cancer in children and young adults.
A new study published in the journal Clinical Chemistry reported Abbott's ARCHITECT Tacrolimus assay provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medication, after receiving solid organ transplantation.
Dr. Reddy's Laboratories Ltd. today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International Financial Reporting Standards.
Veloxis Pharmaceuticals A/S today announced dosing of the first patient in the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) Phase IIIb study of LCP-Tacro in kidney transplant recipients experiencing drug-induced tremors.
A team of researchers grafting human spinal stem cells into rats modeled with amyotrophic lateral sclerosis (ALS), also known as "Lou Gehrig's Disease," a degenerative, lethal, neuromuscular disease, have tested four different immunosuppressive protocols aimed at determining which regimen improved long-term therapeutic effects.
An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.
Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.
Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).
Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury.
Johns Hopkins researchers have developed a way to stimulate a rat's stem cells after a liver transplant as a means of preventing rejection of the new organ without the need for lifelong immunosuppressant drugs.